Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
The company's market capitalization stood at $7.9 billion as of June 30, 2023, reflecting investor confidence. Neurocrine Biosciences Inc ( NASDAQ:NBIX ) is poised to leverage its strengths and opportunities while addressing its weaknesses and threats in the dynamic biopharmaceutical landscape. With a focus on neuroscience, the company continues to innovate with FDA approvals and strategic partnerships, setting the stage for future growth. Warning! GuruFocus has detected 7 Warning Sign with DOV. Neurocrine Biosciences Inc ( NASDAQ:NBIX ), a neuroscience-focused biopharmaceutical company, filed its 10-K on February 9, 2024, revealing a year of significant progress and robust financial health. The company's dedication to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders has translated into a strong financial performance, with INGREZZA net product sales reaching $1.8 billion in 2023. This figure accounted for approximately 99% of the company'
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Reports First Quarter 2024 Financial ResultsPR Newswire
- UPDATE 1-Neurocrine Biosciences' Huntington's disease drug gets FDA approval [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules [Yahoo! Finance]Yahoo! Finance
NBIX
Earnings
- 5/1/24 - Beat
NBIX
Sec Filings
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 4/17/24 - Form 4
- NBIX's page on the SEC website